Fitness, Health and Nutrition

HEALTH

Understand or prevent a condition.

HEALTH

  • An Experimental Tumor-Homing Drug Beat Chemotherapy in Returning Endometrial Cancer

    CATEGORY: WOMEN’S HEALTH

    When endometrial cancer comes back after chemotherapy and immunotherapy, the next treatment usually buys months, not years. A 776-woman international trial just moved that line: women who got an experimental drug called sacituzumab tirumotecan lived a median of 19 months, versus 12.1 months on standard chemotherapy, a 32% lower risk of death during the study.1 The drug isn’t approved yet. US regulators have it under priority review, with a decision due by June 2027.

    776 Women After the Standard Drugs Had Failed

    Every woman in the trial had advanced or recurrent cancer of the endometrium, the lining of the uterus, and every one had already been through platinum chemotherapy and an immunotherapy drug. At 242 hospitals in 31 countries, a computer randomly sorted them into two groups. Half received the new drug by infusion every two weeks. The other half received whichever standard chemotherapy their own oncologist picked, doxorubicin or weekly paclitaxel. Nobody was blinded, so patients and doctors knew the assignment. The outcomes that mattered resist that knowledge: how long women lived, and tumor growth judged from scans by independent radiologists who didn’t know who got what. Follow-up ran a median of 14 months.1

    Sacituzumab tirumotecan is an antibody-drug conjugate. An antibody seeks out TROP2, a protein crowded onto the surface of most endometrial tumor cells, and releases its chemotherapy payload right there. It’s chemotherapy with a delivery address.

    Seven More Months, and Tumors That Shrank Twice as Often

    Median survival was 19.0 months with the new drug and 12.1 months with chemotherapy. A year in, 63.4% of the women on it were alive, versus 50.8% on chemotherapy. The cancer was also held still longer: a median of 7.2 months before growing, against 3.9, a 41% lower risk of progression or death. Tumors shrank in 35.1% of women on the new drug and 17.3% on chemotherapy, and those responses lasted longer too, 11.1 months against 6.9.1

    Who Didn’t Benefit

    The gains weren’t spread evenly. Most participants, about 84%, had tumors whose DNA-repair machinery still works, called mismatch repair proficient, and the survival benefit showed up clearly there. It also showed up in the roughly 80% whose tumors carried medium or high levels of TROP2, the protein the drug homes in on. In the smaller groups the picture changed. Women whose tumors had faulty DNA repair saw no clear survival gain. Neither did women with low TROP2. And in the 48 women with carcinosarcoma, an aggressive rare subtype, chemotherapy actually did better. These subgroup readings come with wide error margins and no formal statistical test behind them, but they sketch who this drug is probably for.1

    Mouth Sores, Low Blood Counts, and a Decision Due in 2027

    The targeting doesn’t make it gentle. Severe treatment-related side effects hit 54.4% of women on the new drug, versus 41.4% on chemotherapy, led by anemia, low levels of oxygen-carrying red blood cells, in 62.5%, and mouth sores in over half, which a preventive steroid mouthwash later blunted. Dry eye affected nearly one in five. Yet fewer women quit the new drug over side effects than quit chemotherapy, 3.1% versus 4.9%, and quality-of-life scores held steady in both groups. Three women in each group died of treatment-related causes. Merck, which is developing the drug, funded and ran the trial. The FDA’s deadline to decide on approval is June 15, 2027.1

    Key Takeaways

    • This drug can’t be prescribed yet: it’s experimental, with a US approval decision expected by mid-2027.
    • In previously treated advanced endometrial cancer, it extended median survival from 12.1 to 19.0 months and lowered the risk of death by 32% compared with standard chemotherapy.
    • The benefit concentrated in the most common tumor types; women with DNA-repair-deficient tumors, low TROP2, or carcinosarcoma saw no clear gain, and the rare carcinosarcoma group fared better on chemotherapy.
    • Side effects were frequent but manageable enough that fewer women stopped the new drug than stopped chemotherapy, and quality of life stayed level in both groups.

    References

    1. Lorusso D, Martin-Babau J, Backes F, et al. Sacituzumab tirumotecan versus treatment of physician’s choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial. The Lancet. 2026; DOI 10.1016/S0140-6736(26)02099-4 (published online October 26, 2026). link
    For educational purposes only — not medical advice. Consult your clinician before acting on this content.

    Found this useful? Please share it!

    Link copied!

    Stay up to date! Subscribe to our FREE weekly newsletter.

    Follow us:

    More from HEALTH!

  • Four Medical Societies Mapped Women’s Heart Risk From First Period Through Menopause

    Heart disease kills more than 400,000 American women every year. That's more than breast cancer, lung cancer and chronic lung disease combined. Yet only about four in ten women name it as their biggest health threat. This week, the American… Read More →

  • A Mailed Vape Kit Helped Smokers Quit, Even Without Coaching Calls

    Most people who try to quit smoking never sit across from a counselor. A British trial of 1,170 smokers asked what happens if you skip that step entirely: mail people an e-cigarette starter kit and let them get on with… Read More →

  • Antihistamine Pills Came Up Short Against Eczema

    The allergy pill didn't help the eczema. That's the short version of a review pooling 47 randomized trials in 6,230 children and adults, published in The BMJ. On a ten-point itch scale, antihistamines (drugs that block histamine, the chemical behind… Read More →

  • An Intensive Burst of Exposure Therapy Outperformed Online Self-Help for OCD

    On one side, a self-guided online therapy program lasting eight weeks. On the other, four consecutive days of intensive, therapist-led treatment. In a German trial of 119 adults with obsessive-compulsive disorder, the four days won decisively: at three months, 61%… Read More →

  • Routine Checkups Caught Type 1 Diabetes Years Before Symptoms in Young Children

    Could a routine pediatric checkup catch type 1 diabetes years before a child feels sick? Researchers in Bavaria, Germany spent a decade finding out, adding a blood test to routine visits for 220,476 young children. The test found an early,… Read More →

  • Against a Standard MS Pill, an Experimental Tablet Cut Relapses Further

    Could a new class of multiple sclerosis pill actually beat an approved therapy, not just match it? That question had a discouraging history. Two large trials now answer it: remibrutinib, an experimental tablet, had relapse rates 35.2% lower in one… Read More →

  • People With a Fast-Moving Lung Cancer Lived Longer With an Added Immune Therapy

    For people with extensive-stage small cell lung cancer, the hardest stretch often comes after the first treatment works. Chemotherapy plus immunotherapy beats the disease back, maintenance immunotherapy continues, and then everyone waits, because this cancer usually returns within months. A… Read More →

  • Blood Pressure That Resists Treatment Got Its Own Playbook From Cardiologists

    The American College of Cardiology has published a step-by-step playbook for blood pressure that won't come down, formally called resistant hypertension: readings still at 130/80 mm Hg or higher despite three medicines at the highest tolerated doses, or pressure that… Read More →

  • Adding Gene Therapy Injections to Radiation Kept Prostate Cancer Away Longer

    Can a prostate tumor be turned into its own vaccine? That question drove a phase 3 trial of CAN-2409, a gene therapy injected directly into the prostate while men underwent standard radiation for localized prostate cancer. Among 745 men followed… Read More →